Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced.

This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.

Inclusion Criteria:

• Male aged 18 years or older
• Diagnosed with prostate cancer
• Patient having received an antagonist of GnRH Degarelix prescription.
• Agreeing to and capable of completing in French during the visits all questionnaires on the impact of their illness and treatment.
• Patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written Informed Consent Form.

Exclusion Criteria:

• Patient included in an interventional study assessing treatment for prostate cancer.
• Patient presenting hypersensitivity to Degarelix or one of its excipients.
• Patient treated by other hormonotherapy.